Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine
Open Access
- 6 July 2025
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 115 (4) , 380-390
Abstract
JAKoMo was a long‐term, multicenter, non‐interventional study observing the efficacy, safety, and quality of life (QOL) effects of ruxolitinib (RUX), managed per clinical routine at investigator discretion, for treatment of 943 patients with myelofibrosis (MF) in 122 German centers. Patients ≥ 18 years with a diagnosis of PMF or PPV‐MF or PET‐MF, who were suitable for in‐label treatment with RUX were eligible and could be included either before (479 previously RUX‐naïve [Arm A]) or after the start of treatment (464 RUX‐experienced patients [Arm B]) and were followed over 36 months. Arm A showed rapid (≤ 6 months), sustained improvements from baseline in all efficacy outcomes and most QOL measures. Both arms showed an ~17% increase in the proportion of patients experiencing a normal German QOL during follow‐up. Arm B entered the study with better outcomes and QOL than Arm A, with outcomes generally remaining stable over time. Adverse events were less common than in registrational trials, possibly due, in part, to lower real‐world RUX dosing. Survival was comparable to published data. The JAKoMo study demonstrates that real‐world RUX treatment of MF promotes significant and sustained clinical and QOL benefits, including improvement of general health and alleviation of MF‐associated fatigue. Maximum sustained responses were generally achieved within 6 months and associated with fewer adverse events than in published randomized trials, which may reflect more conservative and personalized real‐world dosing.Trial Registration: The JAKOMO trial: http://clinicaltrials.gov/show/NCT05044026Keywords
Funding Information
- Novartis Pharma
This publication has 16 references indexed in Scilit:
- The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real‐world study on AIFA monitoring registriesBritish Journal of Haematology, 2024
- International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic dataBlood, 2022
- A prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosisBlood Advances, 2022
- Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet countsBritish Journal of Haematology, 2020
- Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based StudyJournal of Clinical Oncology, 2015
- A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosisHaematologica, 2015
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosisBlood, 2013
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for MyelofibrosisNew England Journal of Medicine, 2012
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for MyelofibrosisNew England Journal of Medicine, 2012
- The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): International Prospective Validation and Reliability Trial in 402 patientsBlood, 2011